IP Library Granted Patent US 10,493,145
Granted Patent B2
US 10,493,145 · App. 16/104,226 · Granted Dec 3, 2019

Immunogenic rhinovirus peptides

Inventors: Guy Baudoux (Rixensart, BE); Mathieu Boxus (Rixensart, BE); Brigitte Colau (Rixensart, BE); Martine Marchand (Rixensart, BE)
Assignee: GlaxoSmithKline Biologicals SA
A61K39/125A61K39/12A61K39/39C07K7/08C07K14/005C07K14/085C12N7/00A61K2039/55566A61K2039/6075A61K2039/6081A61K2039/64C12N2770/32034C12N2770/32334C12N2770/32722C12N2770/32734
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,493,145
App. No.
16/104,226
Granted
Dec 3, 2019
Kind
B2
Abstract

Fusion proteins comprising a carrier protein and a Human Rhinovirus (HRV) peptide, and immunogenic compositions containing such fusion proteins.

Claims (12)

1. An immunogenic composition comprising (a) a fusion protein, said fusion protein comprising a carrier protein coupled to a human rhinovirus (HRV) peptide of no more than 40 amino acids, said HRV peptide comprising a sequence selected from SEQ ID NO: 1; and (b) a pharmaceutically acceptable diluent, excipient or carrier.

2. The immunogenic composition of claim 1 , wherein said carrier protein is CRM197.

3. The immunogenic composition of claim 1 , further comprising an adjuvant.

4. The immunogenic composition of claim 3 , wherein said adjuvant comprises QS21.

5. The immunogenic composition of claim 3 , wherein said adjuvant comprises 3D-MPL and QS21 in a liposome formulation.

6. A fusion protein comprising a carrier protein coupled to a HRV peptide of no more than 40 amino acids, said HRV peptide comprising a sequence selected from SEQ ID NO: 1.

7. The fusion protein of claim 6 , wherein said carrier protein is CRM197.

8. A method for preparing an immunogenic composition, the method comprising combining (a) a fusion protein comprising a carrier protein coupled to a human rhinovirus (HRV) peptide of no more than 40 amino acids, said HRV peptide comprising a sequence selected from SEQ ID NO: 1; and (b) a pharmaceutically acceptable diluent, excipient, or carrier.

9. The method of claim 8 , wherein said carrier protein is CRM197.

10. The method of claim 8 , further comprising combining (c) an adjuvant.

11. The method of claim 10 , wherein said adjuvant comprises QS21.

12. The method of claim 10 , wherein said adjuvant comprises 3D-MPL and QS21 in a liposome formulation.

Continuity (3)
Division 14774729
Provisional Application 61786765 · Mar 15, 2013
Related Publication 20190076519A1 · Mar 14, 2019